Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab + EP vs EP in extensive-stage small cell lung cancer
CTR20180090Phase 3Completed
- Sponsor
- MedImmune
- Start
- May 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in small cell lung cancer (SCLC), sponsored by MedImmune. Started May 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20180090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180090.